Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72611 record(s)

Req # A-2023-001575

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-111864-298.

Organization: Health Canada

8 page(s)
July 2024

Req # A-2023-001615

Adverse Drug Reactions (ADRs). Report numbers: 001069121, E2B_06818695, E2B_06772717.

Organization: Health Canada

13 page(s)
July 2024

Req # A-2023-001622

Adverse Drug Reactions (ADRs) for Mesalimine. Report numbers: E2B_06850804, E2B_06862609. ADRs for CUVITRU. Report numbers: E2B_06897676, E2B_06897774, E2B_06897655, E2B_06897714, E2B_06897705, E2B_06897712, E2B_06897664, E2B_06897688.

Organization: Health Canada

164 page(s)
July 2024

Req # A-2023-001625

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_06860106, E2B_06879090, E2B_06897644. ADRs for Immunoglobulin (human). Report numbers: E2B_06848171, 001069979, 001069986, E2B_06894900, E2B_06839700, E2B_06886486, 001069997.

Organization: Health Canada

129 page(s)
July 2024

Req # A-2023-001631

Adverse Drug Reaction (ADR). Report number: 001069831.

Organization: Health Canada

47 page(s)
July 2024

Req # A-2024-000016

Adverse Drug Reaction (ADR) for EMTRICITABINE/TENOFOVIR. Report number: E2B_06027461.

Organization: Health Canada

10 page(s)
July 2024

Req # A-2024-000076

Adverse Drug Reaction (ADR). Report number: E2B_06011424.

Organization: Health Canada

28 page(s)
July 2024

Req # A-2024-000145

Adverse Drug Reaction (ADR). Report number: E2B_06863508.

Organization: Health Canada

53 page(s)
July 2024

Req # A-2024-000163

Adverse Drug Reactions (ADRs). Report numbers: E2B_06905021, E2B_06904860.

Organization: Health Canada

17 page(s)
July 2024

Req # A-2024-000189

Adverse Drug Reaction (ADR). Report number: E2B_06892006.

Organization: Health Canada

67 page(s)
July 2024
Date modified: